Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy
SENZA-PDN Study is Largest Prospective, Multicenter, Randomized Clinical Trial of Spinal Cord Stimulation Conducted to Date
News provided by
Share this article
REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company has submitted a pre-market approval supplement to the U.S. Food and Drug Administration (FDA) to seek approval of its Senza® System for the treatment of chronic pain associated with Painful Diabetic Neuropathy (PDN).